One could predict that the design of compounds able to specifically target aberrant protein kinase(s) and not their normal counterparts or to target protein kinases whose (over)expression is strictly required for cells undergoing the process of transformation would perhaps turn out to be a more effective strategy to treat cancer. The gene discussed is WEE1; the disease is cancer.